Lelipel 4 mg 14 sachets

Tradename:

Lelipel

Compound:

Each sachet contains:

Montelukast sodium 4.2 mg, equivalent to montelukast 4 mg

Auxiliary components:

Mannitol, hydroxypropyl cellulose, magnesium stearate.

Properties:

Leukotriene receptor antagonist. Montelukast binds with high selectivity and chemical affinity to CysLT1 receptors (instead of other pharmacologically important airway receptors such as prostaglandin, cholinergic or β-adrenergic receptors).

Montelukast inhibits the physiological action of the cisgeinyl leukotrienes LTC4, LTD4 and LTE4 by binding to the CysLT1 receptors without stimulating these receptors. Montelukast inhibits CysLT1 receptors in the epithelium of the respiratory tract, thus simultaneously possessing the ability to inhibit bronchospasm caused by inhalation of LTD4 in patients with bronchial asthma.

Montelukast causes bronchodilation within 2 hours of oral administration and may supplement bronchodilation induced by beta2-agonists.

Indications:

Prevention and long-term treatment of bronchial asthma, including: prevention of day and night symptoms of the disease; treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid; prevention of exercise-induced bronchospasm.

Relief of daytime and nighttime symptoms of seasonal allergic rhinitis.

Dosage and administration:

Montelukast is taken by mouth.

Children from 2 to 5 years old take 4 mg (1 sachet) per day.

Children from 6 months to 2 years of age to relieve asthma take 1 sachet of 4 mg once a day.

It is necessary to strictly observe the regimen of therapy. It is recommended to continue treatment even when significant clinical improvement is achieved.

Contraindications:

Hypersensitivity to montelukast; children’s age – depending on the dosage form.

Precautionary measures:

The efficacy of oral montelukast in the treatment of acute asthma attacks has not been established. Therefore, oral montelukast is not recommended for the treatment of acute asthma attacks. Patients should be instructed to carry emergency asthma medications (short-acting inhaled beta2-agonists) with them at all times.

The dose of inhaled corticosteroids used concomitantly with montelukast can be gradually reduced under the supervision of a physician, however, a sharp replacement of inhaled or oral corticosteroids with montelukast cannot be carried out.

Side effects:

Infectious diseases: very often – infections of the upper respiratory tract.

From the nervous system: infrequently – headache, dizziness, drowsiness, paresthesia / hypoesthesia, convulsions.

From the side of the cardiovascular system: rarely – palpitations.

From the respiratory system: infrequently – nosebleeds; very rarely – pulmonary eosinophilia.

From the digestive system: often – diarrhea, nausea, vomiting.

From the side of the liver and biliary tract: often – an increase in the activity of ALT and ACT.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains 14 sachets with granules, paper instructions.